Advertisement

Topics

Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Monoclonal Antibodies

08:00 EST 27 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Arsanis awarded up to $9.3 million from the Bill & Melinda Gates Foundation to advance RSV antibody program towards the clinic Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal anti...

Other Sources for this Article

Arsanis:
Media
Ten Bridge Communications
Krystle Gibbs, 508-479-6358
krystle@tenbridgecommunications.com
or
Investors:
Michael Gray, 781-819-5201
Chief Financial and Chief Business Officer
mike.gray@arsanis.com
or
Adimab:
Guy Van Meter, 603-653-5775
Vice President, Business Development
Guy.vanmeter@adimab.com

NEXT ARTICLE

More From BioPortfolio on "Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Monoclonal Antibodies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...